Serological response to pneumococcal vaccination in HAART-treated HIV-infected patients: one year follow-up study.
Vaccine
; 24(14): 2567-74, 2006 Mar 24.
Article
em En
| MEDLINE
| ID: mdl-16423429
ABSTRACT
The aim of this study was to evaluate specific IgG responses against pneumococcal serotypes 1, 6B, 14, 19F, 23F at baseline, 1 and 12 months after vaccination with the 23-valent polysaccharide pneumococcal vaccine in 89 HAART-treated HIV-infected patients, 24 antiretroviral "naïve" HIV-infected and 30 non-HIV-infected healthy subjects. Levels of specific antipneumococcal IgG and the mean fold increase in IgG levels at 1 month as well as the kinetics of antibodies along the 12 months in all groups of HIV-infected patients and healthy subjects were similar. Neither CD4 cell count at baseline nor "nadir" CD4 cells correlated with the response to the vaccine. In conclusion, the immunogenicity conferred by the polysaccharide vaccine in HIV-infected patients under HAART is at least as good as that observed in healthy subjects.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Infecções Pneumocócicas
/
Infecções por HIV
/
Contagem de Linfócito CD4
/
Vacinas Pneumocócicas
Tipo de estudo:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Adult
/
Humans
Idioma:
En
Ano de publicação:
2006
Tipo de documento:
Article